Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: A proof-of-concept study

Annals of Oncology

Volumn 28, Issue 8, 2017, Pages 1996-2001

  Cabel, L ^a   Riva, F ^a   Servois, V ^a   Livartowski, A ^a   Daniel, C ^a   Rampanou, A ^a   Lantz, O ^b   Romano, E ^a,b   Milder, M ^b   Buecher, B ^a   Piperno Neumann, S ^a   Bernard, V ^a   Baulande, S ^a   Bieche, I ^a   Y Pierga, J ^a,c   Proudhon, C ^a   Bidard, François Clément ^a,d  

^a INSTITUT CURIE   (France)

^b PSL RESEARCH UNIVERSITY   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Biomarker; Circulating tumor DNA; Immune therapy; Nivolumab; Pembrolizumab

Indexed keywords

CIRCULATING TUMOR DNA; DNA; NIVOLUMAB; PEMBROLIZUMAB; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; DNA DETERMINATION; DRUG EFFICACY; DRUG MONITORING; HUMAN; MIDDLE AGED; MONOTHERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; TUMOR VOLUME; UVEA MELANOMA; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; BLOOD; FEMALE; IMMUNOTHERAPY; MALE; NEOPLASM; PATHOLOGY; PHYSIOLOGIC MONITORING; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL ANALYSIS;

AGED; AGED, 80 AND OVER; B7-H1 ANTIGEN; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASMS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 85027542426     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx212     Document Type: Article

References (21)

1. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373(17): 1627-1639
2. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373(2): 123-135
3. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med 2015; 373(1): 23-34
4. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med 2015; 372(26): 2509-2520
5. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med 2015; 373(19): 1803-1813
6. Nghiem PT, Bhatia S, Lipson EJ et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. N. Engl. J. Med 2016; 374(26): 2542-2552
7. Bidard F-C, Weigelt B, Reis-Filho JS. Going with the flow: from circulating tumor cells to DNA. Sci. Transl. Med 2013; 5(207): 207ps14
8. Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014; 32(6): 579-586
9. Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 2016; 6(5): 479-491
10. Diehl F, Schmidt K, Choti MA et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med 2008; 14(9): 985-990
11. Siravegna G, Mussolin B, Buscarino M et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med 2015; 21(7): 795-801
12. Riva F, Bidard F-C, Houy A et al. Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer. Clin. Chem 2017; 63: 691-699
13. Olsson E, Winter C, George A et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol. Med 2015; 7(8): 1034-1047
14. Lipson EJ, Velculescu VE, Pritchard TS et al. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J. Immunother. Cancer 2014; 2(1): 42
15. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res 2009; 15(23): 7412-7420
16. Madic J, Piperno-Neumann S, Servois V et al. Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. Clin Cancer Res 2012; 18(14): 3934-3941
17. Bidard F-C, Ychou M, Madic J et al. Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial. Ann. Oncol 2016; 27(suppl 6): 456O
18. Karachaliou N, Mayo-de las Casas C, Queralt C et al. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol 2015; 1(2): 149-157
19. Bettegowda C, Sausen M, Leary RJ et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med 2014; 6(224): 224ra24
20. Pécuchet N, Zonta E, Didelot A et al. Base-position error rate analysis of next-generation sequencing applied to circulating tumor DNA in non-small cell lung cancer: a prospective study. PLoSMed 2016; 13(12): e1002199
21. Maier J, Lange T, Kerle I et al. Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA. Clin Cancer Res 2013; 19(17): 4854-4867